{"id":305548,"date":"2019-11-19T23:00:39","date_gmt":"2019-11-20T07:00:39","guid":{"rendered":"https:\/\/nai500.com\/?p=305548"},"modified":"2019-11-19T23:01:11","modified_gmt":"2019-11-20T07:01:11","slug":"%e4%b8%ad%e5%9b%bd%e4%b8%89%e7%94%9f%e5%88%b6%e8%8d%af%e9%80%89%e6%8b%a9%e9%9d%b6%e5%90%91%e6%8a%97%e4%bd%93-vtx-0811","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hans\/blog\/2019\/11\/%e4%b8%ad%e5%9b%bd%e4%b8%89%e7%94%9f%e5%88%b6%e8%8d%af%e9%80%89%e6%8b%a9%e9%9d%b6%e5%90%91%e6%8a%97%e4%bd%93-vtx-0811\/","title":{"rendered":"\u4e2d\u56fd\u4e09\u751f\u5236\u836f\u9009\u62e9Verseau\u7684PSGL-1\u9776\u5411\u6297\u4f53VTX-0811"},"content":{"rendered":"<p><strong>PSGL-1\u662f\u514d\u75ab\u7597\u6cd5\u7684\u65b0\u578b\u9776\u6807\uff0c\u53ef\u8bf1\u5bfc\u5de8\u566c\u7ec6\u80de\u91cd\u7f16\u7a0b\u5e76\u6fc0\u6d3b\u534f\u540c\u7684\u6297\u80bf\u7624\u708e\u75c7\u53cd\u5e94<\/strong><\/p>\n<p>\u4e09\u751f\u5236\u836f\uff08HKEX\uff1a1530\uff09\u548cVerseau Therapeutics, Inc.\uff08\u201c Verseau\u201d\uff09 \u6839\u636e\u53cc\u65b9\u7814\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u591a\u79cd\u764c\u75c7\u7684\u521b\u65b0\u5355\u514b\u9686\u6297\u4f53\u7684\u5408\u4f5c\u534f\u8bae\uff0c\u5df2\u9009\u53d6PSGL-1\u9776\u70b9\u7684\u5355\u514b\u9686\u6297\u4f53VTX-0811\u4f5c\u4e3a\u7b2c\u4e00\u4e2a\u6388\u6743\u4ea7\u54c1\u3002<\/p>\n<p>\u901a\u8fc7\u9776\u5411PSGL-1\uff08\u4e00\u79cd\u7c98\u9644\u5206\u5b50\uff0c\u8be5\u7c98\u9644\u5206\u5b50\u5728\u5927\u591a\u6570\u7c7b\u578b\u7684\u80bf\u7624\u76f8\u5173\u7684\u5de8\u566c\u7ec6\u80de\u4e0a\u9ad8\u8868\u8fbe\uff09\uff0cVTX-0811\u5c06\u5de8\u566c\u7ec6\u80de\u91cd\u7f16\u7a0b\u4e3a\u4fc3\u708e\u72b6\u6001\uff0c\u6fc0\u6d3bT\u7ec6\u80de\u5e76\u5438\u5f15\u5176\u4ed6\u514d\u75ab\u7ec6\u80de\u4ea7\u751f\u534f\u540c\u800c\u5f3a\u5927\u7684\u6297\u80bf\u7624\u836f\u54cd\u5e94\u3002\u4e0e\u76ee\u524d\u7684\u514d\u75ab\u7597\u6cd5\u76f8\u6bd4\uff0cVerseau\u7684PSGL-1\u6297\u4f53\u5728PD-1\u53cd\u5e94\u6027\u548c\u975e\u53cd\u5e94\u6027\u80bf\u7624\u4e2d\u5747\u8868\u73b0\u51fa\u66f4\u5927\u7684\u708e\u75c7\u53cd\u5e94\u3002 PSGL-1\u662fVerseau\u5de8\u566c\u7ec6\u80de\u68c0\u67e5\u70b9\u8c03\u8282\u5668\uff08MCM\uff09\u7cfb\u5217\u4e2d\u7684\u7b2c\u4e00\u4e2a\u975e\u76f2\u76ee\u76ee\u6807\u3002 Verseau\u7684MCM\u6839\u636e\u75be\u75c5\u60c5\u51b5\u5c06\u5de8\u566c\u7ec6\u80de\u91cd\u65b0\u7f16\u7a0b\u4e3a\u66f4\u5177\u708e\u75c7\u6027\u6216\u81f4\u8010\u53d7\u6027\u3002<\/p>\n<p>Verseau\u9996\u5e2d\u6267\u884c\u5b98Christine Bunt\u535a\u58eb\u8bf4\uff1a\u201c\u6211\u4eec\u5f88\u9ad8\u5174\u5728\u4e0e\u4e09\u751f\u5236\u836f\u7684\u5408\u4f5c\u4e2d\u5b9e\u73b0\u4e86\u6211\u4eec\u7684\u7b2c\u4e00\u4e2a\u8bb8\u53ef\u91cc\u7a0b\u7891\u3002\u4ed6\u4eec\u9009\u62e9VTX-0811\u4f5c\u4e3a\u7b2c\u4e00\u4e2a\u5f00\u53d1\u8ba1\u5212\u7684\u51b3\u5b9a\u8bc1\u5b9e\u4e86PSGL-1\u662f\u91cd\u8981\u4e14\u65b0\u9896\u7684\u514d\u75ab\u80bf\u7624\u9776\u6807\uff0c\u6709\u671b\u6269\u5927\u5176\u5e94\u7528\u8303\u56f4\u3002\u6211\u4eec\u7684\u521b\u65b0\u5408\u4f5c\u4f19\u4f34\u5173\u7cfb\u4f7fVerseau\u80fd\u591f\u63a8\u52a8\u6211\u4eec\u884c\u4e1a\u9886\u5148\u7684\u5de8\u566c\u7ec6\u80de\u68c0\u67e5\u70b9\u8c03\u8282\u5242\u4ea7\u54c1\u7ebf\uff0c\u5728\u5404\u79cd\u764c\u75c7\u7597\u6cd5\u4e2d\u5177\u6709\u4e00\u6d41\u7684\u6f5c\u529b\u3002\u201d<\/p>\n<p>\u4e09\u751f\u5236\u836f\u8463\u4e8b\u957f\u517c\u9996\u5e2d\u6267\u884c\u5b98\u5a04\u7ade\u8868\u793a\uff1a\u201c\u60a3\u8005\u6765\u6e90\u7684\u539f\u53d1\u6027\u80bf\u7624\u65e9\u671f\u6570\u636e\u8868\u660e\uff0c\u4e0e\u76ee\u524d\u7684\u514d\u75ab\u7597\u6cd5\u76f8\u6bd4\uff0c\u5728\u5bf9PD-1\u6709\u54cd\u5e94\u548c\u65e0\u54cd\u5e94\u7684\u80bf\u7624\u4e2d\uff0cPSGL-1\u6297\u4f53\u53ef\u4ee5\u4ea7\u751f\u66f4\u5f3a\u7684\u6297\u80bf\u7624\u708e\u75c7\u53cd\u5e94\u3002\u901a\u8fc7\u4e0eVerseau\u7684\u5408\u4f5c\uff0c\u6211\u4eec\u6b65\u5165\u4e86\u514d\u75ab\u80bf\u7624\u5b66\u9886\u57df\u6700\u6709\u524d\u666f\u7684\u521b\u65b0\u9886\u57df\u7684\u524d\u6cbf\uff0c\u5e76\u671d\u7740\u4e3a\u4e2d\u56fd\u7684\u60a3\u8005\u5e26\u6765\u764c\u75c7\u65b0\u7597\u6cd5\u7684\u76ee\u6807\u9010\u6b65\u524d\u8fdb\u3002\u6211\u4eec\u671f\u5f85\u4ece\u6b64\u6b21\u9009\u62e9\u7684\u7b2c\u4e00\u4e2a\u9879\u76ee\u5f00\u59cb\u542f\u52a8\u5f00\u53d1\uff0c\u540c\u65f6\u4e5f\u671f\u5f85\u672a\u6765Verseau\u7684\u5168\u4eba\u6e90\u8f6c\u5316\u533b\u5b66\u7cfb\u7edf\u7b5b\u9009\u51fa\u66f4\u591a\u65b0\u7684\u5de8\u566c\u7ec6\u80de\u9776\u70b9\u9879\u76ee\u3002\u201d<\/p>\n<p>\u6839\u636e\u534f\u8bae\u6761\u6b3e\uff0c\u4e09\u751f\u5236\u836f\u5c06\u83b7\u5f97\u5728\u8be5\u533a\u57df\u7684\u72ec\u5bb6\u8bb8\u53ef\uff0c\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u4e00\u7cfb\u5217\u9002\u7528\u4e8e\u6240\u6709\u4eba\u7c7b\u80bf\u7624\u9002\u5e94\u75c7\u7684\u5de8\u566c\u7ec6\u80de\u68c0\u67e5\u70b9\u8c03\u8282\u5242\u6297\u4f53\u3002Verseau\u4fdd\u7559\u5927\u4e2d\u534e\u533a\u4ee5\u5916\u6240\u6709\u5de8\u566c\u7ec6\u80de\u68c0\u67e5\u70b9\u8c03\u8282\u5242\u9879\u76ee\u7684\u5168\u7403\u6743\u76ca\u3002Verseau\u5c06\u8d1f\u8d23\u5de8\u566c\u7ec6\u80de\u68c0\u67e5\u70b9\u8c03\u8282\u5242\u6297\u4f53\u4ea7\u54c1\u7684\u65e9\u671f\u53d1\u73b0\u548c\u4f18\u5316\u3002\u4e09\u751f\u5236\u836f\u5c06\u5728\u8be5\u533a\u57df\u5f00\u5c55\u5de8\u566c\u7ec6\u80de\u68c0\u67e5\u70b9\u8c03\u8282\u5242\u6297\u4f53\u4e34\u5e8a\u524d\u548c\u4e34\u5e8a\u5f00\u53d1\u3001\u4ea7\u54c1\u751f\u4ea7\u3001\u65b0\u836f\u6ce8\u518c\u548c\u5546\u4e1a\u5316\u7b49\u4e8b\u5b9c\u3002Verseau\u548c\u4e09\u751f\u5236\u836f\u5c06\u6709\u8d44\u683c\u5728\u8be5\u533a\u57df\u548c\u5168\u7403\u8303\u56f4\u5185\u83b7\u5f97\u4ea7\u54c1\u9500\u552e\u7684\u7279\u5b9a\u91cc\u7a0b\u7891\u4ed8\u6b3e\u548c\u7279\u8bb8\u6743\u4f7f\u7528\u8d39\u3002<\/p>\n<p>\u82f1\u6587\u6765\u6e90\uff1aBiospace<\/p>\n","protected":false},"excerpt":{"rendered":"<p>3SBio Inc. (&#8220;3SBio&#8221;) (HKEX:1530) and Verseau Therapeutics, Inc. (&#8220;Verseau&#8221;) today announced the selection of VTX-0811, a monoclonal antibody targeting PSGL-1, as the first licensed program under their partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers.<\/p>\n","protected":false},"author":9,"featured_media":255302,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[427],"tags":[455,925,459],"class_list":["post-305548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-news-zh-hans","tag-455","tag-925","tag-459","sectors-life-science-zh-hans","locations-china-zh-hans","locations-us-zh-hans"],"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/305548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=305548"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/posts\/305548\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media\/255302"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/media?parent=305548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/categories?post=305548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hans\/wp-json\/wp\/v2\/tags?post=305548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}